Chinanews.com Client, February 25th (Zhang Ni), Deputy Director of the State Intellectual Property Office, He Zhimin said on the 25th that Radixivir is a new drug being developed by Gilead Sciences of the United States. Currently, the drug is in any country in the world None have been approved for marketing and are in clinical stage. A number of Chinese hospitals in Wuhan have started clinical trials of the drug, and the results of the clinical trials will not be announced until April 27. Regarding Radixiway, Gilead Science has applied for 8 patents in China, 3 patents have been authorized, and 5 are under review. The scope of protection of 8 patent applications covers the core structure of compounds and similar structures. Related manufacturing methods, uses, etc. He said that if a patentee thinks that there is an infringement, he can bring a lawsuit to the court in accordance with the law or submit a request for administrative arbitration to the relevant department. We will protect the legitimate rights and interests of the patentee within the framework of the patent law.